BCIQ Profiles

Company Profile Report
0604 Tmunity
BioCentury & Getty Images

Product Development

What Tmunity is and isn’t changing after deaths that grounded its PSMA CAR program

Same targets, but more stringent patient selection protocols and optimized cell engineering

After neurotoxicity events, Tmunity is adopting more stringent patient selection protocols for its solid tumor CAR T cell trials and optimizing cell engineering, but it’s sticking with the same targets.

Jun 5, 2021 | 1:18 AM GMT

In the aftermath of three program-ending neurotoxicity events, Tmunity is upping the baseline scrutiny of patients enrolling in its solid tumor CAR

Read the full 881 word article

How to gain access

Continue reading with a
two-week free trial.